Does use of PDE5 inhibitors post-treatment affect risk for biochemical recurrence?

A new article in the February 2015 of the Journal of Urology may actually tell us as much (or more) about the difficulties of relying on data from large, retrospective analyses of single institution data as it does about the actual issue references in the headline above. … READ MORE …

Avanafil shows benefit against ED in prostate cancer patients post-surgery

According to media information released earlier today by Vivus, Inc., the company’s selective, investigational phosphodiesterase type 5 (PDE5) inhibitor known as avanafil has shown positive results in a randomized, double-blind, multi-center, placebo-controlled Phase III clinical trial for the treatment of erectile dysfunction (ED) in patients after a radical prostatectomy. … READ MORE …

Prostate cancer news update: Tuesday, August 19

Recent publications reported on today include:

  • Demonstration of the validity of the Epstein criteria in defining pathologically insignificant prostate cancer
  • A review of the value of sildenafil (Viagra) and similar products in treatment of erectile dysfunction among prostate cancer patients
  • A review of the significance of “gene fusion” and its relevance in prostate cancer … READ MORE …